These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6539697)

  • 1. Corynebacterium parvum toxicity in patients with limited and advanced malignancy.
    Hirshaut Y; Pinsky CM; Wanebo HJ; Braun DW
    Eur J Cancer Clin Oncol; 1984 May; 20(5):583-91. PubMed ID: 6539697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma.
    Gall SA; DiSaia PJ; Schmidt H; Mittelstaedt L; Newman P; Creasman W
    Am J Obstet Gynecol; 1978 Nov; 132(5):555-60. PubMed ID: 717456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonspecific immunotherapy by Corynebacterium parvum: phase I toxicity study in 12 patients with advanced cancer.
    Cheng VS; Suit HD; Wang CC; Cummings C
    Cancer; 1976 Apr; 37(4):1687-95. PubMed ID: 769937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
    Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
    Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
    J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study.
    Fisher B; Rubin H; Sartiano G; Ennis L; Wolmark N
    Cancer; 1976 Jul; 38(1):119-30. PubMed ID: 947509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group.
    J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
    Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
    Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study on the treatment of women with cervical cancer, stage IIB, IIIB, and IVA (confined to the pelvis and/or periaortic nodes), with radiotherapy alone versus radiotherapy plus immunotherapy with intravenous Corynebacterium parvum: a Gynecologic Oncology Group Study.
    DiSaia PJ; Bundy BN; Curry SL; Schlaerth J; Thigpen JT
    Gynecol Oncol; 1987 Mar; 26(3):386-97. PubMed ID: 3549476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA; Bartolucci AA; Smalley RV; Vogler WR
    Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.
    Rao B; Wanebo HJ; Ochoa M; Lewis JL; Oettgen HF
    Cancer; 1977 Feb; 39(2):514-26. PubMed ID: 837334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
    Gusdon JP; Homesley HD; Jobson VW; Muss HB
    Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A; Gutterman JU; Bodey GP; Hersh EM
    Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary study of intralesional, intralymph node, intravenous and intraperitoneal Corynebacterium parvum treatments in patients with advanced cancer.
    Cheng VS; Suit HD; Wang CC; Raker J; Weymuller E; Kaufman S
    Cancer; 1978 Oct; 42(4):1912-5. PubMed ID: 709538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity from cancer immunotherapy.
    Dosik GM; Gutterman JU; Hersh EM; Akhtar M; Sonoda T; Horn RG
    Ann Intern Med; 1978 Jul; 89(1):41-6. PubMed ID: 666183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
    Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
    Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
    Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
    J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model.
    Knapp RC; Berkowitz RS
    Am J Obstet Gynecol; 1977 Aug; 128(7):782-6. PubMed ID: 560124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic and immunologic side effects of daily C. parvum-infusion in treatment-resistant cancer patients.
    Mayr AC; Westerhausen M; Senn HJ
    Dev Biol Stand; 1977 Apr 13-15; 38():523-7. PubMed ID: 608546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.